Evaluation of a connexin-based peptide for the treatment of age-related macular degeneration
A critical target in age-related macular degeneration (AMD) is the retinal pigment epithelium (RPE), which forms the outer blood-retina barrier (BRB). RPE-barrier dysfunction might result from the disruption of intercellular tight junctions (TJs). A Connexin43 (Cx43)-based peptide, aCT1, has been sh...
Main Authors: | Elisabeth Obert, Christina Grek, Gautam Ghatnekar, Bärbel Rohrer |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-11-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844022026470 |
Similar Items
-
Twenty Years of Anti-Vascular Endothelial Growth Factor Therapeutics in Neovascular Age-Related Macular Degeneration Treatment
by: Bo-Hyun Moon, et al.
Published: (2023-08-01) -
Oxidative Stress and Antioxidants in Age-Related Macular Degeneration
by: Neetu Kushwah, et al.
Published: (2023-07-01) -
Research progress of tight junction between retinal pigment epithelium cells and its disruption in the pathogenesis of age-related macular degeneration
by: Qiao-Yun Wang, et al.
Published: (2023-02-01) -
Second eyes to develop neovascular age-related macular degeneration have fewer symptoms and better one-year visual outcomes
by: F. Sema Akkan Aydoğmuş, et al.
Published: (2023-07-01) -
Molecular Mechanisms of Retinal Pigment Epithelium Dysfunction in Age-Related Macular Degeneration
by: Jongmin Kim, et al.
Published: (2021-11-01)